MEDI6469, a murine anti-human OX40 agonist antibody was studied in a phase Ib trial with 17 patients with locally advanced HNSCC prior to definitive surgical resection [56]. This evidence concerns the gene TNFRSF4 and head and neck squamous cell carcinoma.